1.The principles of surgical treatment in malignant pelvic tumors.
Chinese Journal of Surgery 2008;46(12):881-883
2.Application of liquid biopsy in the diagnosis and treatment of colorectal cancer
Chinese Journal of Laboratory Medicine 2017;40(4):227-230
Liquid biopsy plays an important role in the process of precision medical treatment.Its clinical value in the diagnosis and treatment of various diseases has being constantly proved.Colorectal cancer with high incidence begins subtly.The applicaiton of efficient early screening and diagnostic methods can effectively reduce the disease damage,and the implementation of precise post-operative and medication monitoring as the guidance for therapeutic strategy is helpful to improve the prognosis of patients.We should seize the opportunity to promote the transformation of research findings into the clinical application of colorectal cancer.Clinicians,technicians and regulators should face up and work together to overcome the challenges met during the process of clinical liquid biopsy.
4.Liquid biopsy:from bench to bedside
Chinese Journal of Laboratory Medicine 2021;44(3):179-180
Researchers have made remarkable progress in developing more advanced assays of liquid biopsy in recent year. More studies have demonstrated the tremendous potential of liquid biopsy biomarkers in changing cancer diagnosis and treatment scenarios. Facing unprecedented opportunities and challenges, scientists must achieve a vital milestone by transforming liquid biopsy from research experimental methods into a molecular diagnostic product with clear clinical utilization.
5.The significance of a set of standardized analytical run in clinical tests with liquid chromatography mass spectrometry
Chinese Journal of Laboratory Medicine 2021;44(5):363-366
Liquid chromatography-mass spectrometry (LC-MS) technology is playing an increasingly important role in clinical precision medicine. Laboratory medicine professionals should pay attention to the universal applicability and particularity of LC-MS technology in quality management. The C62-A guideline issued by the Clinical and Laboratory Standards Institute (CLSI) stipulates that LC-MS must meet the need of special 'additional quality assurance' -analytical run setting, which is worthwhile for reference. We need to establish a specific strategy for a set of standardized analytical run which is suitable for medical laboratories in China, aiming to ensure the accuracy of results of LC-MS tests.